Julia von Schnurbein1, Jaida Manzoor2, Stephanie Brandt3, Friederike Denzer3, Katja Kohlsdorf3, Pamela Fischer-Posovszky3, Mario Weißenberger3, Sabine Frank-Podlech4,5,6, Saqib Mahmood7, Martin Wabitsch3. 1. Division of Pediatric Endocrinology and Diabetes, Ulm University Hospital, Ulm, Germany, julia.schnurbein@uniklinik-ulm.de. 2. The Children's Hospital and Institute of Child Health, Lahore, Pakistan. 3. Division of Pediatric Endocrinology and Diabetes, Ulm University Hospital, Ulm, Germany. 4. Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany. 5. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, German Center for Diabetes Research (DZD), Tübingen, Germany. 6. Department of Internal Medicine IV, University Hospital, Tübingen, Germany. 7. Department of Human Genetics and Molecular Biology, University of Health Sciences Lahore, Lahore, Pakistan.
Abstract
BACKGROUND AND OBJECTIVE: Hyperleptinemia is supposed to play a causal role in the development of obesity-associated hypertension, possibly via increased sympathetic tone. Hence patients with congenital leptin deficiency should be hypotensive and their low blood pressure should increase under leptin substitution. SUBJECTS AND METHODS: To test this assumption, we examined ambulatory blood pressure, resting heart rate, Schellong test results, cold pressor test results, heart rate variability, catecholamine metabolites, and aldosterone levels in 6 patients with congenital leptin deficiency before as well as 2-7 days and 7-14 months after the start of leptin substitution. Ambulatory blood pressure was also examined in 3 patients with biallelic disease-causing variants in the leptin receptor gene. RESULTS: Contrary to our expectations, even before leptin substitution, 1 patient with biallelic leptin receptor gene variants and 4 patients with leptin deficiency had been suffering from hypertension. Short-term substitution with leptin increased blood pressure further in 3 out of 4 patients (from 127.0 ± 11.7 to 133.8 ± 10.6 mm Hg), concomitant with an increase in resting heart rate as well as in heart rate during the Schellong test in all patients (from 87.6 ± 7.7 to 99.9 ± 11.0 bpm, p = 0.031, and from 102.9 ± 13.5 to 115.6 ± 11.3 bpm, p = 0.031, respectively). Furthermore, the systolic blood pressure response during the cold pressor test increased in 4 out of 6 patients. Unexpectedly, catecholamine metabolites and aldosterone levels did not increase. After long-term leptin substitution and weight loss, the resting heart rate decreased in 4 out of 6 patients compared to baseline, and in all patients below the heart rate seen immediately after the start of therapy (from 99.9 ± 11.0 to 81.7 ± 5.4 bpm; p = 0.031). CONCLUSIONS: These results show that obesity-associated hypertension does not depend on the presence of leptin. However, short-term leptin substitution can increase the blood pressure and heart rate in obese humans with leptin deficiency, indicating that leptin plays at least an additive role in obesity-associated hypertension. The mechanisms behind this are not clear but might include an increase in regional sympathetic tone.
BACKGROUND AND OBJECTIVE: Hyperleptinemia is supposed to play a causal role in the development of obesity-associated hypertension, possibly via increased sympathetic tone. Hence patients with congenital leptin deficiency should be hypotensive and their low blood pressure should increase under leptin substitution. SUBJECTS AND METHODS: To test this assumption, we examined ambulatory blood pressure, resting heart rate, Schellong test results, cold pressor test results, heart rate variability, catecholamine metabolites, and aldosterone levels in 6 patients with congenital leptin deficiency before as well as 2-7 days and 7-14 months after the start of leptin substitution. Ambulatory blood pressure was also examined in 3 patients with biallelic disease-causing variants in the leptin receptor gene. RESULTS: Contrary to our expectations, even before leptin substitution, 1 patient with biallelic leptin receptor gene variants and 4 patients with leptin deficiency had been suffering from hypertension. Short-term substitution with leptin increased blood pressure further in 3 out of 4 patients (from 127.0 ± 11.7 to 133.8 ± 10.6 mm Hg), concomitant with an increase in resting heart rate as well as in heart rate during the Schellong test in all patients (from 87.6 ± 7.7 to 99.9 ± 11.0 bpm, p = 0.031, and from 102.9 ± 13.5 to 115.6 ± 11.3 bpm, p = 0.031, respectively). Furthermore, the systolic blood pressure response during the cold pressor test increased in 4 out of 6 patients. Unexpectedly, catecholamine metabolites and aldosterone levels did not increase. After long-term leptin substitution and weight loss, the resting heart rate decreased in 4 out of 6 patients compared to baseline, and in all patients below the heart rate seen immediately after the start of therapy (from 99.9 ± 11.0 to 81.7 ± 5.4 bpm; p = 0.031). CONCLUSIONS: These results show that obesity-associated hypertension does not depend on the presence of leptin. However, short-term leptin substitution can increase the blood pressure and heart rate in obese humans with leptin deficiency, indicating that leptin plays at least an additive role in obesity-associated hypertension. The mechanisms behind this are not clear but might include an increase in regional sympathetic tone.
Authors: Allyn L Mark; Khristofor Agassandian; Donald A Morgan; Xuebo Liu; Martin D Cassell; Kamal Rahmouni Journal: Hypertension Date: 2008-12-22 Impact factor: 10.190
Authors: Stephanie E Simonds; Jack T Pryor; Eric Ravussin; Frank L Greenway; Ralph Dileone; Andrew M Allen; Jaspreet Bassi; Joel K Elmquist; Julia M Keogh; Elana Henning; Martin G Myers; Julio Licinio; Russell D Brown; Pablo J Enriori; Stephen O'Rahilly; Scott M Sternson; Kevin L Grove; David C Spanswick; I Sadaf Farooqi; Michael A Cowley Journal: Cell Date: 2014-12-04 Impact factor: 41.582
Authors: Vernicia Hernandez; Kavaljeet Kaur; Mohamed W ElSharief; Sari W Al Hajaj; Ahmed M Ebrahim; Mirash Razack; David Dragas Journal: Cureus Date: 2021-06-20